Audit of performance of needle core biopsy diagnoses of screen detected breast lesions.
Breast needle core biopsy (NCB) is now a standard diagnostic procedure in the triple assessment of screen detected breast lesions. Therefore, it is important to provide robust and up-to-date data on the performance of NCB in the screening setting. However, previous studies of NCB have suffered from either limitation in the number of assessed cases or included a mix of symptomatic and screen detected breast lesions. In this study, we have evaluated the performance of a large series of uniformly assessed NCBs of screen detected lesions (20001 cases) over a period of 10 years (1997-2007). Our results showed a gradual increase in the number of NCBs and an improvement of their performance over the period of the study; absolute sensitivity increased from 84.9% to 96.4% and complete sensitivity increased from 90.9% to 99.7%. There was also a gradual reduction in the number of surgical interventions after benign (B2) and negative (B1) NCB diagnoses. Our study provides data showing variance from the suggested thresholds for the measures of performance of NCB in the United Kingdom which could be used to provide updated evidence-based thresholds for assessment of performance of NCB diagnosis use in the assessment of breast cancer screen detected lesions in the UK and elsewhere.
El-Sayed
Maysa E
ME
Molecular Medical Sciences, University of Nottingham, Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham, UK.
Rakha
Emad A
EA
Reed
Jacquie
J
Lee
Andrew Hs
AH
Evans
Andrew J
AJ
Ellis
Ian O
IO
D001707:Biopsy, Needle / Q000592:standards*; D001940:Breast / Q000473:pathology*; D001943:Breast Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D008485:Medical Audit; D011785:Quality Assurance, Health Care; D011787:Quality of Health Care; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D016526:Workload